Contact
searchSearch
HMP Global

RSV Vaccines Topic Center

Featured Article

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
Quiz
RSV Vaccine Eligibility
06/21/2023
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now receive the FDA-approved RSV vaccine Arexvy?
What patient demographic can now...
06/21/2023
First Report Managed Care

Newsfeed

Quiz
Estimated Fatality Rate of RSV in Older Adults
08/28/2023
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or older, what is the estimated fatality rate of RSV?
Among adults aged 60 years or...
08/28/2023
First Report Managed Care
News
RSV Vaccine Combo Shows Promise for Enhanced Protection
08/22/2023
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
Quiz
Testing Results of the Bivalent RSV Prefusion F Vaccine
08/14/2023
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a result of administering the bivalent RSV prefusion F vaccine in older adults?
What has NOT been found as a...
08/14/2023
First Report Managed Care
News
RSV Prefusion F Vaccine Prevents RSV Illness in Older Adults
08/10/2023
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
Quiz
RSV Vaccine Potential Economic Savings
07/26/2023
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV vaccine with coverage and efficacy similar to influenza vaccination could save the US economy how much money in direct medical costs per RSV season?
Researchers suggest an RSV...
07/26/2023
First Report Managed Care
News
RSV Vaccination in US Older Adults Could Save Up to $1 Billion Per Season
07/24/2023
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
Quiz
Key Features of RSV mRNA Vaccine Development
07/21/2023
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV mRNA vaccine that must be accounted for in the vaccine development process? 
What is a key feature of the RSV...
07/21/2023
First Report Managed Care
News
Cell-Based Relative Potency Assay Assessed for RSV Vaccine Development
07/19/2023
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
Trial Finds Lower Viral Load, Symptom Scores With MVA-BN-RSV Vaccine
06/27/2023
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
Mapping the Diversity and Evolution of RSV T Cell Epitopes for Vaccine Design
06/26/2023
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care
FRMC Volume 21, Issue 3

Current Issue

September 2024
Volume 21
Issue 3
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use